CN206342738U - Series connection blood processor comprising plasma separator and cyto-centrifuge - Google Patents
Series connection blood processor comprising plasma separator and cyto-centrifuge Download PDFInfo
- Publication number
- CN206342738U CN206342738U CN201620733616.4U CN201620733616U CN206342738U CN 206342738 U CN206342738 U CN 206342738U CN 201620733616 U CN201620733616 U CN 201620733616U CN 206342738 U CN206342738 U CN 206342738U
- Authority
- CN
- China
- Prior art keywords
- blood
- catheter
- upstream
- plasma
- separation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
The utility model is related to a kind of series connection blood processor comprising plasma separator and cyto-centrifuge, including：Cyto-centrifuge；Plasma separator；The the first upstream blood catheter and the first downstream blood catheter being connected with plasma separator；With the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein described second upstream blood catheter and the connection of the first downstream blood catheter, or first upstream blood catheter and the second downstream blood catheter connection, so that the cyto-centrifuge and the plasma separator are into series connection.The utility model further relates to the control system for the blood processor.
Description
Technical field
The application is related to medical instruments field, more particularly, to a kind of blood processor with cascaded structure.
Background technology
Hepatic failure patients carry out autologous peripheral blood stemcell transplant, need to carry out stem cell collection, however, such conditions of patients weight,
Generally require to carry out plasma exchange supportive treatment.Normal practice is that patient receives single replacement therapy of blood plasma, first sets up external
Peripheral passage, plasma treatment machine is connected by patient, carries out replacement therapy of blood plasma, about 2-4 hours time；Autologous peripheral blood is dry thin
Born of the same parents' collection is then acquired using single blood cell separator, need to re-establish extracorporal circulatory system path, time-consuming about to need 2-3 small
When.
Plasma exchange, stem cell collection are originally the clinical technologies being used alone, and need to carry out doing thin for hepatic failure patients
, it is necessary to which using two kinds of therapeutic modalities, the shortcoming carried out respectively is that patient need to set up extracorporal circulatory system path repeatedly, many during born of the same parents' collection
Secondary addition anti-coagulants, and external anti-freezing increased risk, are lengthened while treatment is time-consuming, cause the discomfort and clinical wind of patient
Danger.
Utility model content
The purpose of this utility model is for needing controlling for the hepatic failure patients of progress stem cell collection and plasma exchange
Treat there is provided a kind of blood processor with cascaded structure, plasma separator and cyto-centrifuge are connected in series, simultaneously
Plasma exchange, two treatments of stem cell collection are carried out, so as to improve therapeutic efficiency, patient's Operative risk are reduced.
The utility model includes herein below：
A kind of blood processor of embodiment 1., it is characterised in that including：
Cyto-centrifuge；
Plasma separator；
The the first upstream blood catheter and the first downstream blood catheter being connected with plasma separator；With
The the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the connection of the first downstream blood catheter, or first upstream blood catheter and
Second downstream blood catheter connection, so that the cyto-centrifuge and the plasma separator are into series connection.
Blood processor of the embodiment 2. according to embodiment 1, it is characterised in that also include：With described
One upstream blood catheter or the anti-coagulants injection conduit of the second upstream blood catheter connection.
Blood processor of the embodiment 3. according to embodiment 1, it is characterised in that also include：With described
The blood plasma injection conduit or displacement liquid injection conduit of one downstream blood catheter connection.
Blood processor of the embodiment 4. according to any one of embodiment 1-3, it is characterised in that wherein institute
State cyto-centrifuge and be configured to blood of the separation from the second upstream blood catheter and obtain the second separation blood and dry thin
Born of the same parents, and the second separation blood is entered the second downstream blood catheter.
Blood processor of the embodiment 5. according to any one of embodiment 1-3, it is characterised in that wherein institute
State plasma separator be configured to separation the blood from the first upstream blood catheter obtain the first separation blood and blood plasma, and
The first separation blood is set to enter the first downstream blood catheter.
Blood processor of the embodiment 6. according to any one of embodiment 1-3, it is characterised in that also wrap
Include：The second flow regulation meter being connected with second upstream blood catheter.
Blood processor of the embodiment 7. according to embodiment 1 or 2, it is characterised in that also include：With it is described
The first flow regulation meter of first upstream blood catheter connection.
Blood processor of the embodiment 8. according to embodiment 2, it is characterised in that also including with the anti-freezing
The anti-coagulants injector of agent injection conduit connection, it is configured for injecting anti-coagulants.
Blood processor of the embodiment 9. according to embodiment 3, it is characterised in that also including with the blood plasma
The blood plasma injector of conduit connection is injected, it is configured for injecting fresh plasma.
Blood processor of the embodiment 10. according to embodiment 1, it is characterised in that the blood treatment dress
Blood volume in putting is less than 500ml.
A kind of control system for being used to operate the blood processor any one of embodiment 1-10 of embodiment 11.
System, it is characterised in that the control system includes software and hardware, the control system is configured to operate the blood as follows
Liquid processing device：
Pending blood is flowed through the first upstream blood catheter and enter plasma separator, plasma separator will be pending
Blood carries out separating treatment and obtains the first separation blood, and the first separation blood is entered the first downstream blood catheter；
The blood in the first downstream blood catheter is set to enter the second upstream blood catheter and enter cyto-centrifuge；
Blood in second upstream blood catheter is carried out separating treatment and obtains the second separation blood by cyto-centrifuge, and
The second separation blood is set to enter the second downstream blood catheter.
Cyto-centrifuge is in the case of the downstream of plasma separator, and the control system of the blood processor can be with
Correspondingly configure.
By means of the technical solution of the utility model, suffer from for the hepatic failure for needing to carry out stem cell transplantation and plasma exchange
The treatment of person, it is only necessary to set up an extracorporeal circulation of blood, while two treatments of plasma exchange and stem cell collection are carried out, so that
Treatment time is shortened, therapeutic efficiency is improved, patient's Operative risk is reduced.
Brief description of the drawings
In order to illustrate more clearly of the technical scheme of the embodiment of the present disclosure, the accompanying drawing of embodiment will be simply situated between below
Continue, it should be apparent that, drawings in the following description merely relate to some embodiments of the present disclosure, rather than limitation of this disclosure.
Fig. 1 is a kind of schematic diagram of embodiment of the application.
Fig. 2 is a kind of schematic diagram for being used to operate the control system of blood processor.
In figure, reference has following meanings：
D：Cyto-centrifuge；F：Plasma separator；
EF：First upstream blood catheter；
FGH：First downstream blood catheter；G：Blood plasma injects conduit or displacement liquid injection conduit access point；
BD：Second upstream blood catheter；
DE：Second downstream blood catheter；
P1：First flow regulation meter；
P2：Second flow regulation meter；
C：Anti-coagulants injects conduit access point；
11：Control system.
Embodiment
To make the purpose, technical scheme and advantage of the embodiment of the present disclosure clearer, below in conjunction with the embodiment of the present disclosure
Accompanying drawing, the technical scheme to the embodiment of the present disclosure is clearly and completely described.Obviously, described embodiment is this public affairs
A part of embodiment opened, rather than whole embodiments.Based on described embodiment of the disclosure, ordinary skill
The every other embodiment that personnel are obtained on the premise of without creative work, belongs to the scope of disclosure protection.
Hepatic failure patients carry out autologous peripheral blood stemcell transplant, need to carry out stem cell collection, however, such conditions of patients weight,
Generally require to be supported treatment by carrying out plasma exchange.Normal practice is that patient receives single replacement therapy of blood plasma,
Extracorporal circulatory system path is first set up, patient is connected into plasma treatment machine, replacement therapy of blood plasma, about 2-4 hours time is carried out；It is autologous
Peripheral blood progenitor collection is then acquired using single blood cell separator, need to re-establish extracorporal circulatory system path, is taken
About need 2-3 hours.
Plasma exchange mainly first isolates blood plasma, the blood of patient is drawn into external, by membrane plasma separation method
The blood plasma of patient is separated from whole blood and discarded, the displacement such as fresh frozen plasma or human serum albumin of equivalent is then supplemented
Liquid.During plasma exchange, separated plasma can use plasma separator.The supplement of frozen plasma is often in the downstream of plasma separator
Complete.
The acquisition method of peripheral hematopoietic stem cells (PBSC) can use the single of cyto-centrifuge separation collection peripheral blood
Nucleus component.Many program separation using separation lymphocyte.The descending big venipuncture of ordinary circumstance, foundation is followed in vitro
Ring is acquired.VPV during collection adult is 50-60ml/min, and 4-6 circulations (about 2-3h), separation are separated every time
The total measurement (volume) 9L of blood, according to situation it is continuous or the next day gather.
Conventional plasma displacement, stem cell collection individually carry out being respectively provided with preferable security and effect.Plasma exchange can be with
The various metabolic toxicities and virulence factor in patient's body are removed, so as to reach therapeutic purposes.Because plasma exchange not only can be with
Remove in vivo in, the metabolic toxicities of small molecule, the macromolecular substances such as albumen, immune complex are also removed, while supplement again
The required materials such as the albumin, the clotting factor that are lacked in vivo, preferably instead of some functions of liver.Peripheral hematopoietic stem cells
(PBSC) acquisition method belongs to ripe clinical application technique at present, and target requirement amount can be preferably collected according to demand
Cell quantity.
Plasma exchange, stem cell collection are originally the clinical technologies being used alone, and need to carry out doing thin for hepatic failure patients
, it is necessary to which using two kinds of therapeutic modalities, the shortcoming carried out respectively is that patient need to set up extracorporal circulatory system path, body repeatedly during born of the same parents' transplanting
Outer anti-freezing increased risk, the time-consuming addition for the treatment of, causes the discomfort and clinical risk of patient.
The purpose of this utility model is for needing controlling for the hepatic failure patients of progress stem cell transplantation and plasma exchange
Treat there is provided a kind of blood processor with cascaded structure, plasma separator and cyto-centrifuge are connected in series, simultaneously
Plasma exchange, two treatments of stem cell collection are carried out, so as to improve therapeutic efficiency, patient's Operative risk are reduced.
Fig. 1 shows a kind of blood processor, and it includes：
Cyto-centrifuge D；
Plasma separator F；
The the first upstream blood catheter (EF) and the first downstream blood catheter (FGH) being connected with plasma separator；With
The the second upstream blood catheter (BD) and the second downstream blood catheter (DE) being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the connection of the first downstream blood catheter, or first upstream blood catheter and
Second downstream blood catheter connection, so that the cyto-centrifuge and the plasma separator are into series connection.
In Fig. 1, conduit makes indicated by the solid line, and the arrow wherein on solid line represents the flow direction of material in conduit.
The blood processor is used for by will be in a series arrangement connected to for the second blood treatment that haemocyte is separated
The upstream or downstream of first blood treatment of plasma exchange, so that, it is only necessary to setting up an extracorporeal circulation of blood can be same
Shi Jinhang haemocytes are separated and plasma exchange, and result is circulated without individually setting up haemocyte separation, and has saved haemocyte
The time of separating treatment, therapeutic efficiency is improved, reduce patient's Operative risk.
In this application, the processing being connected with plasma separator is referred to as the first processing or the first blood treatment.In this Shen
Please in, the processing being connected with cyto-centrifuge is referred to as second processing or the second blood treatment.
In some instances, the blood processor, in addition to：With first upstream blood catheter or the second upstream
The anti-coagulants injection conduit of blood catheter connection.Anti-coagulants is added from the conduit, it is possible to so that the blood of whole human body is by liver
Elementization (anti-coagulated processing), so that whole blood circulation pipeline disclosure satisfy that the requirement of anti-freezing.
In some instances, the blood processor also includes：The blood plasma being connected with first downstream blood catheter
Inject conduit or displacement liquid injection conduit.In plasma exchange, it is necessary to supplement after original blood plasma in having separated blood
The displacement liquids such as the fresh frozen plasma or human serum albumin of amount, therefore, blood plasma injection conduit are referred to as being displacement liquid note
Enter conduit.
In some instances, in the blood processor, the cyto-centrifuge is configured to separation and come from
Stem cell in the blood of second upstream blood catheter obtains the second separation blood, and the second separation blood is entered the second downstream
Blood catheter.
In some instances, in the blood processor, the plasma separator is configured to separation from the
Blood plasma in the blood of one upstream blood catheter, obtains the first separation blood, and the first separation blood is entered the first downstream blood
Fluid catheter.
In some instances, the blood processor also includes：Second be connected with second upstream blood catheter
Flow-controlling meter P2.
In some instances, the blood processor, in addition to：First be connected with first upstream blood catheter
Flow-controlling meter P1.
In some instances, the blood volume in the blood processor is less than 500ml, preferably shorter than 400ml, more excellent
Choosing is less than 300ml.Make the blood volume in whole blood processor it is relatively low be in order to patient can for ability to bear,
For normal people, discomfort occurs when may work as blood missing (extracorporal circulatory system) more than 500ml, however, for hepatopathy
Patient, possible blood is circulated in vitro just occurs malaise symptoms before reaching 500ml, therefore, in the blood processor
Blood volume it is more low better, preferably shorter than 400ml.
Embodiments herein also provides the method for operating above-described blood processor, including：
Pending blood is set to flow through the first upstream blood catheter into plasma separator F, plasma separator will be pending
Blood carry out separating treatment and obtain the first separation blood, and the first separation blood is entered the first downstream blood catheter；
The blood in the first downstream blood catheter is entered the second upstream blood catheter and enter cyto-centrifuge D；
Blood in second upstream blood catheter is carried out separating treatment and obtains the second separation blood by cyto-centrifuge, and
The second separation blood is set to enter the second downstream blood catheter.
Cyto-centrifuge operates the side of above-described blood processor in the case of the downstream of plasma separator
Method can be carried out similarly.
In some instances, methods described also includes：Conduit is injected to the second upstream blood catheter by the anti-coagulants
Or add anti-coagulants in the first pending blood in the blood catheter of upstream.
In some instances, methods described also includes：Conduit is injected into the first downstream blood catheter by the blood plasma
First separation blood in add blood plasma.
In some instances, in the process, the cyto-centrifuge is configured to separation and comes from the second upstream
Stem cell in the blood of blood catheter obtains the second separation blood, and the second separation blood is led into the second downstream blood
Pipe.
In some instances, the plasma separator is configured in blood of the separation from the first upstream blood catheter
Blood plasma, obtain the first separation blood, and the first separation blood is entered the first downstream blood catheter.
In some instances, methods described also includes：Adjust the second flow regulation meter P2 and first flow regulation meter
At least one in P1, so that the flow in flow and the first blood treatment in the second blood treatment meets outer circulation blood
The requirement of flow velocity.
In some instances, methods described also includes in advance entering described device (including whole pipeline) using heparin saline
Row pipeline pre-flush.In the running of described device, in the second upstream blood catheter of whole pipeline most upstream or first
Upstream blood catheter addition anti-coagulants can just realize the test tube of hepari of overall circulation, and the process of overall test tube of hepari is followed by human body
What ring reached, so as to reduce the consumption of anti-coagulants (heparin).In this application, test tube of hepari and anti-coagulated contain with identical
Justice, makes blood noncondensing effect during handling in vitro all referring to anti-coagulants such as heparin so as to reach is added into blood
Really.
In some instances, methods described also includes：Conduit is injected into the first downstream blood catheter by the blood plasma
First separation blood in add at least one of following material：Fresh plasma or displacement liquid.Therefore, the blood plasma injection is led
Pipe can also turn into displacement liquid and inject conduit.Described displacement liquid can include human serum albumin.
In some examples of methods described, the cyto-centrifuge is configured to separation and comes from the second upstream blood
Stem cell in the blood of conduit obtains the second separation blood, and the second separation blood is entered the second downstream blood catheter.
In some examples of methods described, the plasma separator is configured to separation and led from the first upstream blood
Blood plasma in the blood of pipe, obtains the first separation blood, and the first separation blood is entered the first downstream blood catheter.
In some instances, methods described also includes：Adjust the second flow regulation meter P2 and first flow regulation meter
At least one in P1, so that flow and pressure reach balance in whole circulation.
As shown in Fig. 2 the application also provides a kind of control system 11 for being used to operate described blood processor, it is special
Levy and be, the control system includes software and hardware, the control system is configured to realize method as described above.Figure
2 be schematic diagram, and the specific part of control system is not shown.However, it should be appreciated by those skilled in the art that according to the application
The information provided at present, forms the conventional technical means that the control system is those skilled in the art.Therefore, Ren Heneng
Enough realize the control system of methods described all in the protection domain of the application.
The application also provides a kind of control system for being used to operate described blood processor, it is characterised in that described
Control system includes software and hardware, and the control system is configured to operate the blood processor as follows：
Pending blood is flowed through the first upstream blood catheter and enter plasma separator, plasma separator will be pending
Blood carries out separating treatment and obtains the first separation blood, and the first separation blood is entered the first downstream blood catheter；
The blood in the first downstream blood catheter is set to enter the second upstream blood catheter and enter cyto-centrifuge；
Blood in second upstream blood catheter is carried out separating treatment and obtains the second separation blood by cyto-centrifuge, and
The second separation blood is set to enter the second downstream blood catheter.
Cyto-centrifuge is in the case of the downstream of plasma separator, and the control system of the blood processor can be with
Correspondingly configure.
Embodiment
Using the device shown in Fig. 1,10 patients are treated.As a result it is as shown in the table.
In upper table,
" collection mononuclearcell number (/L) " refers to PMNC (Peripheral blood
Mononuclear cell, PBMC) be the cell in peripheral blood with single core concentration, including lymphocyte, monocyte
With the peripheral blood hematopoietic stem cells being characterized with CD34+ molecular labelings.
It is the mark of hemopoietic stem cell surface that " CD34+ cell numbers (/L) ", which refers to CD34, and CD34+ cell numbers refer to Hematopoietic Stem
The concentration of cell.
" treatment time (h) needed for theoretical " refers to：Traditional treatment carries out controlling needed for plasma exchange and stem cell collection respectively
The summation for the treatment of time.
" actual therapeutic spends the time (h) " refers to：Plasma exchange is carried out using this example and stem cell collection has needs altogether
Real time.
Measurement by the biochemical indicator to patient shows, patient is treated using the blood processor of the disclosure
Compared with the method treated respectively using two traditional steps, therapeutic effect does not have notable difference, but but shortens treatment
Time, alleviate the pain of patient.
Described above is only the exemplary embodiment of the disclosure, not for the protection domain of the limitation disclosure, this public affairs
The protection domain opened is determined by appended claim.
Claims (11)
1. a kind of blood processor, it is characterised in that including：
Cyto-centrifuge；
Plasma separator；
The the first upstream blood catheter and the first downstream blood catheter being connected with plasma separator；With
The the second upstream blood catheter and the second downstream blood catheter being connected with cyto-centrifuge；Wherein
Second upstream blood catheter and the first downstream blood catheter connection, or first upstream blood catheter and second
Downstream blood catheter connection, so that the cyto-centrifuge and the plasma separator are into series connection.
2. blood processor according to claim 1, it is characterised in that also include：Led with first upstream blood
Pipe or the anti-coagulants injection conduit of the second upstream blood catheter connection.
3. blood processor according to claim 1, it is characterised in that also include：Led with first downstream blood
The blood plasma injection conduit or displacement liquid injection conduit of pipe connection.
4. the blood processor according to any one of claim 1-3, it is characterised in that wherein described haemocyte separation
Device is configured to blood of the separation from the second upstream blood catheter and obtains the second separation blood and stem cell, and makes second point
Enter the second downstream blood catheter from blood.
5. the blood processor according to any one of claim 1-3, it is characterised in that wherein described plasma separator
It is configured to blood of the separation from the first upstream blood catheter and obtains the first separation blood and blood plasma, and makes the first separation blood
Liquid enters the first downstream blood catheter.
6. the blood processor according to any one of claim 1-3, it is characterised in that also include：With described second
The second flow regulation meter of upstream blood catheter connection.
7. blood processor according to claim 1 or 2, it is characterised in that also include：With first upstream blood
The first flow regulation meter of conduit connection.
8. blood processor according to claim 2, it is characterised in that also including connecting with anti-coagulants injection conduit
The anti-coagulants injector connect, it is configured for injecting anti-coagulants.
9. blood processor according to claim 3, it is characterised in that also including being connected with blood plasma injection conduit
Blood plasma injector, its be configured for inject fresh plasma.
10. blood processor according to claim 1, it is characterised in that the blood in the blood processor holds
Amount is less than 500ml.
11. a kind of control system that the blood processor any one of 1-10 is required for operational rights, its feature exists
In the control system includes software and hardware, and the control system is configured to operate the blood processor as follows：
Pending blood is flowed through the first upstream blood catheter and enter plasma separator, plasma separator is by pending blood
Carry out separating treatment and obtain the first separation blood, and the first separation blood is entered the first downstream blood catheter；
The blood in the first downstream blood catheter is set to enter the second upstream blood catheter and enter cyto-centrifuge；
Blood in second upstream blood catheter is carried out separating treatment and obtains the second separation blood by cyto-centrifuge, and makes the
Two separation blood enter the second downstream blood catheter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620733616.4U CN206342738U (en) | 2016-07-12 | 2016-07-12 | Series connection blood processor comprising plasma separator and cyto-centrifuge |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201620733616.4U CN206342738U (en) | 2016-07-12 | 2016-07-12 | Series connection blood processor comprising plasma separator and cyto-centrifuge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN206342738U true CN206342738U (en) | 2017-07-21 |
Family
ID=59316115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201620733616.4U Expired - Fee Related CN206342738U (en) | 2016-07-12 | 2016-07-12 | Series connection blood processor comprising plasma separator and cyto-centrifuge |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN206342738U (en) |
-
2016
- 2016-07-12 CN CN201620733616.4U patent/CN206342738U/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI302103B (en) | Metabolic detoxification system and method | |
| EP2586473B1 (en) | Artificial nephron device | |
| Ikomi et al. | Recent advance in lymph dynamic analysis in lymphatics and lymph nodes | |
| WO2018201862A1 (en) | Circulating tumor cell capture device | |
| CN106110421B (en) | Rhesus monkey erythrocytes absorber | |
| CN104225698B (en) | A kind of hepatocyte microsphere circulating biological artificial liver support system | |
| CN108211032A (en) | Combination type biological Artificial Liver Support System | |
| Armignacco et al. | Wearable devices for blood purification: principles, miniaturization, and technical challenges | |
| CN202699700U (en) | Off-line hybrid bio-artificial liver support system (BALSS) | |
| Flessner | Peritoneal ultrafiltration: physiology and failure | |
| CN206342738U (en) | Series connection blood processor comprising plasma separator and cyto-centrifuge | |
| CN206167487U (en) | Connection in series -parallel blood treatment device containing blood cell separator and blood plasma separator | |
| CN203677608U (en) | Device for adopting CRRT machine to perform blood purification united ascites ultra-filtration reinfusion | |
| CN206342739U (en) | Connection in series-parallel blood processor comprising cyto-centrifuge and bioartificial liver devices | |
| CN208770520U (en) | Combination type biological Artificial Liver Support System | |
| CN206151972U (en) | Bioartificial liver processing apparatus and blood cell separator 's series connection blood processing apparatus and control system thereof | |
| CN206342737U (en) | Connection in series-parallel blood processor comprising cyto-centrifuge and bilirubin adsorption device | |
| CN206151973U (en) | Blood treatment device and be used for operating device's control system | |
| CN105727382B (en) | A kind of continous way CRRT machine capability bascules of two tripper | |
| CN205386253U (en) | Bioartificial liver on -line monitoring and integrative system of constant temperature heating | |
| CN207640722U (en) | A kind of haemodialysis equipment | |
| CN205515732U (en) | Continuous type CRRT machine capacity balancing unit | |
| CN205649684U (en) | Discontinuous CRRT machine capacity balancing unit | |
| CN214679564U (en) | Liver support system used in vitro | |
| CN220158875U (en) | Continuous blood purifying pipeline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191121 Address after: 100039 No.100 courtyard, West 4th Ring Middle Road, Fengtai District, Beijing Patentee after: Fifth Medical Center, General Hospital of the Chinese People's Liberation Army Address before: 100039 Department of liver decay, No.302 Hospital, PLA, No. 100 West Fourth Ring Road, Beijing, Fengtai District, China Co-patentee before: Zhu Bing Patentee before: You Shaoli |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170721 Termination date: 20210712 |